Agilent Technologies stock gains on digital pathology launch and strong Q3 figures

Agilent Technologies stock is trading near its recent high as the company launches the Agilent S540MD Slide Scanner System in the U.S. and reports solid Q3 2026 margins and growth, underscoring its position in life science and diagnostics markets.

Agilent Technologies Inc (ISIN US00846U1016) stock is quoted at 149.98 USD as of September 4, 2026, only 1.1% above an intrinsic value estimate of 148.35 USD, according to data compiled by GuruFocus. On the same day, Agilent announced the U.S. launch of its Agilent S540MD Slide Scanner System following FDA approval, adding a new digital pathology solution to its diagnostics portfolio as highlighted in the news feed at StockTitan. For investors, the combination of a nearly fair valuation and fresh product momentum sets the tone for Agilent Technologies stock today.

New S540MD scanner strengthens digital pathology push

On September 4, 2026, Agilent Technologies expanded its digital pathology offering in the U.S. with the launch of the Agilent S540MD Slide Scanner System after receiving FDA clearance, according to the company press summary carried in the StockTitan news stream. The scanner is designed for high volume pathology laboratories and can process up to 540 slides, with continuous loading and compatibility with standard racks as described by GuruFocus. That capacity matters because large hospital and reference labs increasingly seek automated workflows that digitize glass slides and integrate into clinical information systems.

The S540MD platform uses automated scanning and advanced tissue detection technologies to accelerate slide digitization and support comprehensive digital pathology workflows, again per the technical description summarized by GuruFocus. By positioning the S540MD as its version of the Hamamatsu NanoZoomer S540MD system, Agilent leverages proven hardware while adding its own integration and service capabilities for diagnostic customers. For European investors following laboratory automation, the digital pathology expansion is relevant for peers such as Roche and Siemens Healthineers, even though Agilent itself is primarily listed on the New York Stock Exchange.

Q3 2026 margins and GF Score highlight financial strength

Alongside the product launch, GuruFocus spotlights Agilent’s fundamentals, assigning the company a GF Score of 96 out of 100, which places it among the top tier of analyzed firms in terms of profitability, growth, valuation and momentum. Within that composite score, profitability receives a perfect 10 rating, supported by an operating margin of 22.23% and a net margin around 19.53% based on trailing twelve month data referenced in the same analysis. These margin levels are significantly above many diversified industrial and diagnostic peers and underscore why Agilent commands a premium valuation.

Agilent’s trailing price to earnings ratio stands at 29.52 times earnings, slightly below its five year median P E multiple of 30.44 times according to GuruFocus. That comparison means the stock trades at a modest discount to its own historical valuation band, even though the absolute multiple is still elevated compared with broad market indices. Combined with the GF Value framework, which puts intrinsic value at 148.35 USD versus a current price of 149.98 USD, the analysis indicates the stock is fairly valued, with a 1.1 percent difference that leaves only a narrow margin of safety for new investors.

From a balance sheet and risk perspective, GuruFocus notes that Agilent posts an Altman Z Score of 5.18 and a Piotroski F Score of 7, both metrics that point to low bankruptcy risk and generally healthy financial fundamentals. The same article cites a market capitalization of 42.28 billion USD for Agilent, placing it firmly in the large cap segment of global life sciences and diagnostics companies. For investors comparing across sectors, that scale is relevant when weighing Agilent against DACH region peers such as Siemens Healthineers or Roche, which also compete in clinical diagnostics and laboratory instrumentation.

Insider activity and valuation temper the upside

GuruFocus also examines insider and institutional activity around Agilent Technologies. Over the past 12 months, the platform reports approximately 3.1 million USD of insider stock sales and no insider purchases, a pattern that may signal cautious expectations for near term appreciation among company executives. At the same time, nine high profile institutional investors, referred to as gurus by GuruFocus, currently hold positions in Agilent, with four having increased their stakes and six trimming holdings over recent quarters. This mixed picture suggests sustained interest in the stock but with some profit taking after the strong run and robust margins.

Interpreting those signals together with valuation metrics, GuruFocus argues that Agilent’s stock being 1.1 percent above its GF Value estimate implies it is slightly overvalued but essentially fairly priced. Because the trailing P E ratio of 29.52 times sits just under the five year median of 30.44 times, the stock does not look excessively expensive relative to its own history, but neither does it offer a deep discount. For investors in Europe who might access Agilent via international brokerage connections rather than a local Xetra listing, the takeaway is that the shares trade near what quantitative models deem fair value, leaving performance to be driven largely by continued margin strength and new product adoption such as the S540MD scanner.

Analytical instruments underpin growth across segments

Beyond the single scanner product, Agilent’s broader business spans analytical laboratory technologies, including chromatography systems, mass spectrometry instruments, and related software and services. An overview of the company published on September 4, 2026 by Passionate in Marketing notes that Agilent generated revenue of 6.95 billion USD in fiscal year 2025 and employs about 18,000 people worldwide, illustrating its scale in the analytical and clinical laboratory technology space. The same article emphasizes Agilent’s presence in biopharmaceutical, chemical and advanced materials markets, which together account for more than half of its sales.

That diversified end market exposure gives Agilent a degree of resilience, as demand from pharmaceutical research, environmental testing and food safety labs can offset cyclical swings in industrial or academic budgets. Services and consumables tied to installed instrument fleets also provide recurring revenue streams, supporting the strong margins highlighted by GuruFocus. While the fiscal 2025 revenue figure is now historical rather than current, it serves as a reference point for how Agilent scaled its operations ahead of the latest quarter and current product launches like the S540MD.

Agilent Technologies stock near fair value for large cap diagnostics

With a market capitalization around 42.28 billion USD and a price of 149.98 USD as of September 4, 2026 per GuruFocus, Agilent Technologies sits solidly in the large cap segment of global diagnostics and life sciences tools. The stock’s slight premium of 1.1 percent over the GF Value estimate of 148.35 USD reflects investor willingness to pay for high operating margins of 22.23% and a GF Score of 96, even as insiders have collectively sold about 3.1 million USD of shares over the past year. For equity investors, the key questions are whether new offerings, such as the FDA cleared S540MD scanner, can sustain growth and profitability to justify that valuation over time, and how Agilent’s instruments and services will compete against European and global peers in laboratory automation and digital pathology.

Agilent Technologies stock at a glance

• Company: Agilent Technologies Inc
• ISIN: US00846U1016
• Ticker: A
• Trading venue: NYSE
• Price (as of September 4, 2026, 14:02): 149.98 USD
• Market capitalization: 42.28 billion USD (as of September 4, 2026)
• Sector / Industry: Healthcare / Medical Diagnostics and Research
• Index membership: S and P 500